Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | CASP6 | P55212 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 7/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | CNR1 | P21554 | 2/20 | 0.43 |
| ▸ | CNR2 | P34972 | 2/20 | 0.43 |
| ▸ | PIN1 | Q13526 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.40 |
| ▸ | AGXT | P21549 | 1/20 | 0.40 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 1/20 | 0.40 |
| ▸ | PDE2A | O00408 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9901204 | 0.86 | POLB (0.45) | POLBCASP6ALDH1A1GAAPIN1 | |
| SCHEMBL9987222 | 0.84 | CNR1 (0.44) | POLBAPPALDH1A1CNR1CNR2 | |
| SCHEMBL22323930 | 0.83 | APP (0.50) | POLBAPPALDH1A1CNR1CNR2 | |
| SCHEMBL3196355 | 0.83 | CNR1 (0.43) | POLBAPPALDH1A1CNR1CNR2 | |
| SCHEMBL31514820 | 0.83 | CNR1 (0.43) | POLBAPPALDH1A1CNR1CNR2 | |
| SCHEMBL20565236 | 0.82 | AR (0.43) | APPALDH1A1CNR1CNR2PIN1 | |
| SCHEMBL30756269 | 0.82 | PIN1 (0.59) | POLBCASP6ALDH1A1GAACNR1 | |
| SCHEMBL5259611 | 0.82 | POLB (0.67) | POLBCASP6APPALDH1A1GAA | |
| SCHEMBL9987333 | 0.82 | MAOB (0.44) | POLBAPPALDH1A1CNR1CNR2 | |
| SCHEMBL9987933 | 0.82 | PIN1 (0.44) | POLBAPPCNR1CNR2PIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250136586-A1 | Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors | BEIGENE, LTD. (KY) | 2025-05-01 | — | — | US | disclosed |
| EP-4514797-A1 | SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2025-03-05 | — | — | EP | disclosed |
| EP-4514791-A1 | SUBSTITUTED 6- (PYRIMIDIN-4-YL) QUINOLINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BeiGene, Ltd. (KY) | 2025-03-05 | — | — | EP | disclosed |
| CN-119095840-A | Substituted 6- (pyrimidin-4-yl) quinoline compounds as cyclin dependent kinase inhibitors | 百济神州有限公司 | 2024-12-06 | — | — | CN | disclosed |
| CN-119053598-A | Substituted 7- (pyrimidin-4-yl) quinolin-4 (1H) -one compounds as cyclin dependent kinase inhibitors | 百济神州有限公司 | 2024-11-29 | — | — | CN | disclosed |
| US-20240300937-A1 | Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors | BEIGENE, LTD. (KY) | 2024-09-12 | — | — | US | disclosed |
| CN-112823159-B | Aromatic heterocyclic compounds with kinase inhibitory activity | 上海轶诺药业有限公司 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023208172-A1 | SUBSTITUTED 7- (PYRIMIDIN-4-YL) QUINOLIN-4 (1H) -ONE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BEIGENE , LTD. (KY) | 2023-11-02 | — | — | WO | disclosed |
| WO-2023208173-A1 | SUBSTITUTED 6- (PYRIMIDIN-4-YL) QUINOLINE COMPOUNDS AS CYCLIN DEPENDENT KINASE INHIBITORS | BEIGENE , LTD. (KY) | 2023-11-02 | — | — | WO | disclosed |
| US-20210371415-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) | 2021-12-02 | — | — | US | disclosed |
| EP-3854793-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020057669-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | 上海轶诺药业有限公司 | 2020-03-26 | — | — | WO | disclosed |
| US-9334274-B2 | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE HOLDINGS CORPORATION (US) | 2016-05-10 | — | — | US | disclosed |
| US-20140221379-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2014-08-07 | — | — | US | disclosed |
| US-8716303-B2 | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors | INCYTE CORPORATION (US) | 2014-05-06 | — | — | US | disclosed |
| EP-2432555-B1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-D]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-D]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORP (US) | 2014-04-30 | — | — | EP | disclosed |
| EP-2432555-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | Incyte Corporation (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010135650-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION (US) | 2010-11-25 | — | — | WO | disclosed |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | INCYTE CORPORATION | 2010-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210371415-A1 | AROMATIC HETEROCYCLIC COMPOUND WITH KINASE INHIBITORY ACTIVITY | JAK1, JAK2, JAK3 | POLB 3170/4885CASP6 1437/4885APP 4376/4885 |
| US-20100298334-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | POLB 1038/4885CASP6 2333/4885APP 4683/4885 |
| US-20250136586-A1 | Substituted 7-(Pyrimidin-4-yl)Quinolin-4(1H)-One Compounds as Cyclin Dependent Kinase Inhibitors | CDK4, CDK7, CDK8 | POLB 631/4885CASP6 1512/4885APP 4500/4885 |
| US-20240300937-A1 | Substituted 6-(Pyrimidin-4-yl)Quinoline Compounds as Cyclin Dependent Kinase Inhibitors | CDK4, CDK6, CDK2 | POLB 648/4885CASP6 1221/4885APP 4449/4885 |
| US-20140221379-A1 | N-(HETERO)ARYL-PYRROLIDINE DERIVATIVES OF PYRAZOL-4-YL-PYRROLO[2,3-d]PYRIMIDINES AND PYRROL-3-YL-PYRROLO[2,3-d]PYRIMIDINES AS JANUS KINASE INHIBITORS | JAK1, JAK3, JAK2 | POLB 1038/4885CASP6 2333/4885APP 4683/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.